Henry Meds Compounded GLP-1 Status 2026: No Warning Letter, 503A Framing, Current Pricing
This page tracks Henry Meds' compounding operational status — regulatory standing, pricing, and legal picture as of May 2026.
For the full Henry Meds review (clinical model, pricing, platform details), see the Henry Meds review.
Current operational status
Henry Meds is operating. Compounded semaglutide and tirzepatide are being offered to new and existing patients as of May 2026.
FDA warning letter status
Henry Meds has not received an FDA warning letter as of May 2026.
The two major waves of FDA GLP-1 compounding enforcement (September 2025: ~50 warning letters targeting unapproved drug claims; March 2026: ~30 warning letters targeting telehealth marketing and false-equivalence claims) did not name Henry Meds in confirmed public records. We verify this monthly against the FDA warning-letter database.
Legal status
No active patent-infringement lawsuits against Henry Meds have been identified in public court records as of this writing. The Novo Nordisk February 2026 patent suits named specific defendants (Mochi Health, Fella Health, others); Henry Meds was not among those named in available public records. Similarly, Eli Lilly's litigation is primarily focused on different operators.
This status can change. Patent suits are regularly added to court dockets and the litigation landscape in GLP-1 compounding is active.
Regulatory framework
Henry Meds operates under §503A(b)(1)(D) — the patient-specific significant-difference framing that allows compounding of commercially available drugs when the prescriber documents a clinical reason the branded product cannot meet the specific patient's needs. For a full breakdown of these two regulatory pathways, see 503A vs 503B pharmacies explained.
Henry Meds' legal exposure is the same as any remaining 503A GLP-1 provider: the FDA's interpretation that products within 10% of commercial doses are "essentially copies" and do not qualify for the significant-difference exemption. This interpretation is legally contested.
Henry Meds has not received a warning letter under this framing. It operates in the same legal grey zone as Eden, Calibrate (for its compounded tier), and other remaining 503A operators.
Current pricing (verify before enrolling)
| Product | First month | Ongoing |
|---|---|---|
| Compounded semaglutide (standard, ≤1 mg) | $247 | $297/month |
| Compounded semaglutide (above 1 mg) | $247 | $397/month (+$100 surcharge) |
| Compounded tirzepatide | $399 | $449/month |
| Oral compounded semaglutide | lower | ~$249/month |
| Oral compounded tirzepatide | lower | ~$349/month |
The dose-based surcharge is the key pricing variable. Patients who titrate above 1 mg semaglutide (common at maintenance) pay $397/month — above NovoCare's branded Wegovy $349/month flat. At maintenance doses, Henry Meds compounded is not cheaper than branded direct.
Henry Meds charges no separate platform or membership fee. The price listed is all-in: prescriber, medication, shipping, dose-adjustment support.
Comparison with Mochi Health
| Factor | Henry Meds | Mochi Health |
|---|---|---|
| Compounded sema price | $297–397/month (dose-based) | $178/month (flat, all doses) |
| Compounded tirze price | $449/month | $278/month (flat, all doses) |
| Active patent lawsuit | None in public record | Eli Lilly suit proceeding |
| FDA warning letter | None | None |
| Platform fee | None | $79/month membership |
| Insurance PA support | No | Yes |
For patients choosing between Henry Meds and Mochi purely on compounded price: Mochi's flat-rate structure is cheaper at most dose levels, especially for patients who reach maintenance doses above 1 mg. Henry Meds' advantage is the cleaner legal risk profile in current public records and no additional platform fee. For a full comparison of how compounded vs brand semaglutide differ, see that guide. Patients looking to lower costs further can also review cheap GLP-1 alternatives.
For the live tracker of all GLP-1 compounders' warning letter status, see FDA warning letters tracker.
Frequently asked questions
Is Henry Meds still operating in 2026?
Yes. Henry Meds is operating and offering compounded semaglutide and tirzepatide as of May 2026. It has not received an FDA warning letter. No active major patent-infringement lawsuit against Henry Meds has been identified in public court records as of this writing.
Has Henry Meds received an FDA warning letter?
No. As of May 2026, Henry Meds has not received an FDA warning letter. The broader March 2026 enforcement wave (30+ warning letters to GLP-1 platforms) did not name Henry Meds in confirmed public records. We verify monthly against the FDA warning-letter database.
Why is Henry Meds' compounded semaglutide more expensive than NovoCare Wegovy at higher doses?
Henry Meds applies a $100/month surcharge for compounded semaglutide at doses above 1 mg (the 1.5–2 mg maintenance range). At those doses, Henry's price is $397/month. NovoCare's branded Wegovy is $349/month flat (all doses). For patients reaching higher maintenance doses, the price advantage of compounded vs branded reverses at Henry Meds specifically. See the full [Henry Meds review](/providers/henry-meds-review) for an in-depth look at the platform's clinical model and pricing structure.
Does Henry Meds accept insurance?
No. Henry Meds' compounded medication plans are cash-pay only. They cannot be submitted to insurance for reimbursement. HSA/FSA eligible.